Literature DB >> 30950101

External validation of a model to determine risk of progression of Barrett's oesophagus to neoplasia.

Andrew T Kunzmann1, Aaron P Thrift2,3, Brian T Johnston4, Damian T McManus5, Anna T Gavin6, Richard C Turkington7,8, Helen G Coleman1,7.   

Abstract

BACKGROUND: A risk prediction model containing sex, smoking history, Barrett's oesophagus length and presence of low-grade dysplasia was found to identify individuals at a higher risk of progression to oesophageal adenocarcinoma or high-grade dysplasia. AIM: To externally validate the model predicting risk of progression from Barrett's oesophagus to neoplasia and assess the predictive utility of additional factors.
METHODS: We conducted a retrospective cohort study among individuals from the population-based Northern Ireland Barrett's register with a histologically confirmed diagnosis of Barrett's oesophagus (with intestinal metaplasia) between 1993 and 2005. The association between a points based model and risk of progression to high-grade dysplasia or oesophageal adenocarcinoma until 2010 was assessed using Cox Proportional Hazards model. Model performance was assessed using area under the receiver operating characteristics curves (AUROC), sensitivity and specificity.
RESULTS: We identified 1198 individuals with Barrett's oesophagus of whom 54 progressed. The model discriminated reasonably well between progressors and nonprogressors, with an AUROC of 0.70 (95% CI 0.63-0.78). When categorised into low, intermediate and high risk groups, the AUROC was 0.68 (95% CI 0.61-0.74). Compared to using data on dysplasia and segment length for risk stratification, the model resulted in a net reclassification improvement of 20.9%.
CONCLUSIONS: This external validation provides further evidence that a model based on sex, smoking, Barrett's segment length and baseline low-grade dysplasia may help to risk stratify patients after an initial diagnosis of Barrett's oesophagus. The model also performed better than the use of low-grade dysplasia status alone for risk-stratification.
© 2019 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2019        PMID: 30950101     DOI: 10.1111/apt.15235

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  5 in total

Review 1.  Global burden and epidemiology of Barrett oesophagus and oesophageal cancer.

Authors:  Aaron P Thrift
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-02-18       Impact factor: 46.802

2.  External validation of a model determining risk of neoplastic progression of Barrett's esophagus in a cohort of U.S. veterans.

Authors:  Theresa H Nguyen; Aaron P Thrift; Gyanprakash A Ketwaroo; Xianglin L Du; Luis Leon Novelo; Rollin George; Daniel G Rosen; Hashem B El-Serag
Journal:  Gastrointest Endosc       Date:  2022-01-06       Impact factor: 10.396

3.  Prediction of neoplastic progression in Barrett's esophagus using nanoscale nuclear architecture mapping: a pilot study.

Authors:  Prashanthi N Thota; Jalil Nasibli; Prabhat Kumar; Madhusudhan R Sanaka; Amitabh Chak; Xuefeng Zhang; Xiuli Liu; Shikhar Uttam; Yang Liu
Journal:  Gastrointest Endosc       Date:  2022-01-20       Impact factor: 10.396

Review 4.  Management of nondysplastic Barrett's esophagus: When to survey? When to ablate?

Authors:  Max M Puthenpura; Krishna O Sanaka; Yi Qin; Prashanthi N Thota
Journal:  Ther Adv Chronic Dis       Date:  2022-04-12       Impact factor: 5.091

Review 5.  Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma: Implications for Screening and Surveillance.

Authors:  Michael B Cook; Aaron P Thrift
Journal:  Gastrointest Endosc Clin N Am       Date:  2020-10-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.